Wedbush Predicts Pharvaris’ FY2029 Earnings (NASDAQ:PHVS)

Pharvaris (NASDAQ:PHVS) – Equities research analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for Pharvaris in a research note issued to investors on Monday, April 7th. Wedbush analyst L. Chico anticipates that the company will post earnings of $5.99 per share for the year. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.06.

Separately, JMP Securities increased their price objective on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $12.30 on Wednesday. The firm has a 50 day simple moving average of $15.76 and a 200 day simple moving average of $18.46. The company has a market cap of $643.17 million, a PE ratio of -4.39 and a beta of -2.84. Pharvaris has a 52 week low of $11.76 and a 52 week high of $25.50.

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of PHVS. Jane Street Group LLC bought a new position in Pharvaris during the third quarter valued at about $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Pharvaris during the third quarter valued at approximately $906,000. State Street Corp acquired a new stake in Pharvaris in the third quarter worth about $1,000,000. Geode Capital Management LLC lifted its holdings in Pharvaris by 18.4% in the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after buying an additional 5,753 shares during the period. Finally, Barclays PLC acquired a new stake in shares of Pharvaris during the third quarter worth $106,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.